
About Viking Therapeutics
Viking Therapeutics is a publicly listed company based in United States founded in 2012. Small molecule therapies for endocrine and metabolic disorders are developed. Viking Therapeutics has raised $2.5 million across 1 funding round from investors including Ligand Pharmaceuticals. The company has 36 employees. Its chief executive, as recorded, is Brian Lian. Its website vikingtherapeutics.com draws about 31 thousand monthly visits. Viking Therapeutics offers products and services including VK2735, VK2809, VK0214, and VK5211. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its legal entity is VIKING THERAPEUTICS, INC. Its competitors include Neurocrine, Crinetics and Carmot; 3 of its 3 listed competitors have raised funding.
Company details
Viking Therapeutics was founded in 2012 in California, United States, and operates in the biotechnology sector. A portfolio of five therapeutic programs based on small molecules is maintained, targeting endocrine and metabolic disorders. The lead candidate, VK0612, is an oral drug for type 2 diabetes, while VK5211 serves as a non-steroidal selective androgen receptor modulator for cancer cachexia. Three preclinical programs address metabolic diseases and anemia.
- Headquarters California, United States
- Employees 36
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website vikingtherapeutics.com
- Social LinkedIn X
- Legal Name Viking Therapeutics, Inc.
- Net Profit-$359.64 M (USD)-227.05as on Dec 31, 2025
- EBITDA-$392.91 M (USD)-160.94as on Dec 31, 2025
- Total Equity Funding$2.5M (USD)
in 1 rounds
- Latest Funding Round$2.5M (USD), Seed
May 2014
- Investors
- Employee Count36
Products & Services of Viking Therapeutics
Viking Therapeutics offers a comprehensive portfolio of products and services, including VK2735, VK2809, VK0214, and VK5211.
Therapeutic for obesity and metabolic disorders via oral administration.
Treatment for NASH and related metabolic conditions.
Therapy for rare disease X-ALD.
addresses hip fracture and muscle wasting.
Funding Insights of Viking Therapeutics
Viking Therapeutics has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.5M
- Total Rounds 1
- Last Round Seed β $2.5M
- First Round $2.5M
(May 2014)
- Investors Count 1
All 1 funding rounds of Viking Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | $2.5M | Seed | β | β |
1 investors in total: 1 institutional.
Investors in Viking Therapeutics
Viking Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States |
Investor details for Viking Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Viking Therapeutics
25 people are tracked at Viking Therapeutics (18 in leadership, 7 in team); the tracked headcount is 36.
| Name | Role | Group |
|---|---|---|
Brian Lian | CEO | Leadership |
Geoffrey Barker | VP, Pharmaceutical Development | Leadership |
Marianne Mancini | Chief Operating Officer | Leadership |
Nils Olsson | Senior Vice President, Technical Operations | Leadership |
Tavette Neskorik | Sr Director, Clinical Operations | Leadership |
Carol Hall | Human Resources Director | Leadership |
Michael Morneau | VP Finance & Administration | Leadership |
Scott Stubbe | Vice President Clinical Operations | Leadership |
Stephanie Herman | Associate Director | Leadership |
Sean Weigle | Director Of Finance And Controller | Leadership |
Mike Morneau | Vice President, Finance And Administration | Leadership |
Shengxia Ji (Summer) | Director, Statistical Programming And Data Management | Leadership |
Greg Zante | VP Finance & Operations | Leadership |
Medardo Chavez | Executive Director Business Development | Leadership |
Brahmachary Enugurthi | Executive Director, Pharmaceutical Development | Leadership |
Maureen McGonegal Barnes | Executive Director, Pharmaceutical Development | Leadership |
Rebecca Steele | Director, Clinical Operations | Leadership |
Karen Chung | VP Health Economics & Market Access | Leadership |
Rachel Frankenberger | Senior Accounting Manager | Team |
Marietta Aquino | Accounts Payable Lead | Team |
5 more people are available in the full profile.
Complete people profiles for Viking Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Viking Therapeutics
Viking Therapeutics is a publicly listed company on the NASDAQ with ticker symbol VKTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Apr 2015
- Listed onNASDAQ: VKTX
- Listed entityViking Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS92686J1060
- Share price$26.65 (-5.96% on the day) · 2026-10-13
- Market capitalisation$3.39B
- EPS (diluted, trailing year)$-4.66
- Volume (last session)5,739,223
Financials of Viking Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$359.6M | -$392.9M | |
| 2024 | -$110.0M | -$150.6M | |
| 2023 | -$85.9M | -$100.5M | |
| 2022 | -$68.9M | -$70.1M | |
| 2021 | -$55.0M | -$55.4M |
Detailed financial statements for Viking Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Viking Therapeutics
3 dated milestones of Viking Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Viking Therapeutics is founded.
- Funding First funding round of $2.5M.
- IPO Lists on the stock exchange (IPO).
Competitors of Viking Therapeutics
Viking Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, Crinetics and Carmot.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | Disease-modifying therapies for metabolic diseases are developed. |
Detailed competitors of Viking Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Viking Therapeutics
The website of Viking Therapeutics (vikingtherapeutics.com) receives about 31.1K visits a month and ranks #1,156,534 among all websites worldwide, #1,447 in Biotechnology and Pharmaceuticals.
- Monthly visits31.1K
▲ 34.2% vs previous month
- Unique visitors10.3K
per month
- Global rank#1,156,534
among all websites
- Category rank#1,447
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.0
- Average visit49 sec
- DevicesDesktop 39% Β· Mobile 61%
Websites whose visitors overlap most with Viking Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicaltrialsarena.com | 100% | #257,942 | View details | ||
| fiercebiotech.com | 88% | 858.3K | #81,022 | View details | |
drugs.com | drugs.com | 72% | #3,085 | β | |
| lilly.com | 67% | 4.9M | #13,252 | View details | |
firstwordpharma.com | firstwordpharma.com | 60% | #237,108 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 6 similar websites and full traffic analytics for Viking Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Viking Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Viking Therapeutics
Complete news archive for Viking Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viking Therapeutics
Viking Therapeutics was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Viking Therapeutics is headquartered in United States. It is registered at California, United States.
Brian Lian is the CEO of Viking Therapeutics, as recorded in our data.
Viking Therapeutics is a funded company, having raised a total of $2.5M across 1 funding round to date. The company's 1st funding round was a Seed of $2.5M, raised on May 2014.
Viking Therapeutics has 36 employees.
Viking Therapeutics was founded in 2012 in California, United States, and operates in the biotechnology sector. A portfolio of five therapeutic programs based on small molecules is maintained, targeting endocrine and metabolic disorders. The lead candidate, VK0612, is an oral drug for type 2 diabetes, while VK5211 serves as a non-steroidal selective androgen receptor modulator for cancer cachexia. Three preclinical programs address metabolic diseases and anemia.
Viking Therapeutics's top competitors include Crinetics, Neurocrine and Carmot.
Viking Therapeutics offers VK2735, VK2809, VK0214, and VK5211.
Yes, Viking Therapeutics is publicly traded on NASDAQ under the ticker symbol VKTX.
Viking Therapeutics has 1 investor. Key investors include Ligand Pharmaceuticals.
Viking Therapeutics operates through Viking Therapeutics, Inc..
